<![CDATA[ Evolving Adjuvant Therapy in Early-Stage EGFR-Mutated NSCLC: Insights From ADAURA ]]>

Summary: Doctors are changing how they treat a specific type of lung cancer (EGFR-mutated) after a patient has surgery. In the past, doctors might just wait to see if the cancer comes back. Now, thanks to a big study called ADAURA, they use a special targeted medicine called osimertinib. This medicine helps patients live much longer without the disease returning. This exciting update shows exactly why it is so important to test a tumor's DNA right away to get the best personalized care!

Source: cancernetwork URL: cancernetwork.com/view/evolving-adjuvant-therapy-in-early-stage-egfr-mutated-nsclc-insights-from-adaura (opens in new tab)